Please login to the form below

Not currently logged in
Email:
Password:

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits R&D pact with Alnylam on rare disease

Sanofi exits R&D pact with Alnylam on rare disease

Genzyme had previously licensed rights in 2012 to Alnylam’s lead RNAI drug Onpattro (patisiran) for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), which became the first drug in the RNAi class ... The R&D deal was tweaked in January

Latest news

More from news
Approximately 1 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

  • Charting a course for expansion Charting a course for expansion

    a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Drivers of 2014′s Soaring Drug Approvals

    The FDA &EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future launch teams and some of the key areas of focus which could make or break a

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics